GlassScriptPhysician profile
April T Hoffman
NPI 1730198672
$1,667.57
in general payments reported to CMS, 2019-2025
29 companies · $361 in 2025
The $361 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $570 · 2020: $120 · 2022: $140 · 2023: $248 · 2024: $229 · 2025: $361.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $838.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $837.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $304.28 | 2019-2024 | |
| Pfizer INC. | $145.66 | 2019-2024 | |
| Astellas Pharma US INC | $120.98 | 2023-2025 | Veozah |
| Coopersurgical, INC. | $113.93 | 2019-2023 | Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $110.76 | 2019-2025 | |
| Biogen, INC. | $89.13 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $88.79 | 2023-2024 | Myosure Tissue Removal Device, Acessa Provu System, Novasure |
| Exeltis, USA INC. | $87.07 | 2019-2025 | Slynd |
| Sumitomo Pharma America, INC. | $85.08 | 2024-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $60.79 | 2023-2025 | |
| Millicent US INC | $54.78 | 2025 | Femlyv |
| Boston Scientific Corporation | $49.69 | 2019 | |
| Duchesnay USA Incorporated | $48.95 | 2019 | |
| Merck Sharp & Dohme LLC | $45.73 | 2019-2020 | |
| Lupin INC. | $29.03 | 2019-2020 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Minerva Surgical, INC | $23.79 | 2019 | |
| Allergan, INC. | $22.04 | 2019 | |
| Organon LLC | $21.71 | 2024-2025 | Nexplanon |
| Innovation Technologies INC | $19.85 | 2025 | Irrisept |
| Shield Therapeutics INC | $16.79 | 2023 | Accrufer |
| Kerecis Limited | $16.72 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Axsome Therapeutics, INC. | $15.91 | 2024 | Auvelity |
| Vertical Pharmaceuticals, LLC | $15.33 | 2019 | |
| Roche Diagnostics Corporation | $14.32 | 2019 | |
| Covidien LP | $13.94 | 2020 | |
| Daiichi Sankyo INC. | $13.91 | 2019 | |
| Avanos Medical | $13.74 | 2019 | |
| Coloplast Corp | $12.81 | 2020 | |
| Therapeuticsmd, INC. | $12.06 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.